Dec 31, 2022

Penumbra Q4 2022 Earnings Report

Penumbra reported an 8.4% increase in revenue for Q4 2022, with vascular products growing by 14.2% and neuro products by 1.2%.

Key Takeaways

Penumbra, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022. Total revenue increased to $221.2 million for the fourth quarter of 2022 compared to $204.0 million for the fourth quarter of 2021, an increase of 8.4%, or 10.5% in constant currency.

Total revenue increased to $221.2 million for the fourth quarter of 2022, an 8.4% increase compared to Q4 2021.

US revenue for Q4 2022 was $157.1 million, 8.8% above the same period a year ago.

Revenue from sales of vascular products grew to $129.7 million, a 14.2% increase.

Revenue from sales of neuro products grew to $91.5 million, a 1.2% increase.

Total Revenue
$221M
Previous year: $204M
+8.4%
EPS
$0.16
Previous year: $0.1
+60.0%
Gross Margin
62.6%
Previous year: 61.5%
+1.8%
Gross Profit
$138M
Previous year: $125M
+10.4%
Cash and Equivalents
$69.9M
Previous year: $59.4M
+17.6%
Free Cash Flow
-$2.23M
Previous year: -$17.4M
-87.2%
Total Assets
$1.37B
Previous year: $1.24B
+10.2%

Penumbra

Penumbra

Penumbra Revenue by Segment

Penumbra Revenue by Geographic Location

Forward Guidance

Penumbra projects total revenue for 2023 to be $1 billion or more, representing year over year growth of at least 18%, which is an acceleration from 2022 revenue of $847 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income